Chawla Bhavna, Agarwal Prakashchand, Tandon Radhika, Titiyal Jeewan S, Sharma Namrata, Agarwal Tushar, Navak Niranjan, Satpathy Gita
Cornea and Refractive Surgery Service, Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Eur J Ophthalmol. 2010 Mar-Apr;20(2):300-5. doi: 10.1177/112067211002000207.
To study the microbiological profile of bacterial keratitis in Northern India and to determine the antibiotic sensitivity pattern of bacterial keratitis isolates to fourth-generation fluoroquinolones.
Laboratory records of all consecutive cases of clinically suspected bacterial corneal ulcers were retrospectively reviewed. Data noted included microorganism isolated and antibiotic culture sensitivity to cefazolin, tobramycin, gatifloxacin, and moxifloxacin. In vitro susceptibility toward individual antibiotics was determined and compared with the potential in vitro susceptibilities to cefazolin-tobramycin, cefazolin-gatifloxacin, and cefazolin-moxifloxacin combinations.
A total of 292 bacterial isolates were identified. Of these, 255 (87.3%) were Gram-positive and 37 (12.7%) were Gram-negative. Staphylococcus epidermidis (n=227, 77.7%) was the most common organism. Overall susceptibility of isolates was 95.52% to gatifloxacin, 92.83% to moxifloxacin, 90.07% to tobramycin, and 83.56% to cefazolin (p<0.000). Organisms which showed resistance to fourth-generation fluoroquinolones included Staphylococcus epidermidis, Pseudomonas aeruginosa, viridans streptococci, Streptococcus pneumoniae, Staphylococcus aureus, and Escherichia coli. Susceptibilities to gatifloxacin and moxifloxacin were comparable with each other (p=0.312) and with potential susceptibilities to cefazolin-tobramycin (p=0.479), gatifloxacin-cefazolin (p=0.134), and moxifloxacin-cefazolin (p=0.412) combinations.
Monotherapy with moxifloxacin or gatifloxacin can be an effective alternative to cefazolin-tobramycin combination as a first-line empirical therapy for bacterial keratitis. The addition of cefazolin to a fourth-generation fluoroquinolone is of limited value.
研究印度北部细菌性角膜炎的微生物学特征,并确定细菌性角膜炎分离株对第四代氟喹诺酮类药物的抗生素敏感性模式。
对所有连续的临床疑似细菌性角膜溃疡病例的实验室记录进行回顾性分析。记录的数据包括分离出的微生物以及对头孢唑林、妥布霉素、加替沙星和莫西沙星的抗生素培养敏感性。测定了对各抗生素的体外敏感性,并与头孢唑林 - 妥布霉素、头孢唑林 - 加替沙星和头孢唑林 - 莫西沙星联合用药的潜在体外敏感性进行比较。
共鉴定出292株细菌分离株。其中,255株(87.3%)为革兰氏阳性菌,37株(12.7%)为革兰氏阴性菌。表皮葡萄球菌(n = 227,77.7%)是最常见的病原体。分离株对加替沙星的总体敏感性为95.52%,对莫西沙星为92.83%,对妥布霉素为90.07%,对头孢唑林为83.56%(p < 0.000)。对第四代氟喹诺酮类药物耐药的病原体包括表皮葡萄球菌、铜绿假单胞菌、草绿色链球菌、肺炎链球菌、金黄色葡萄球菌和大肠杆菌。加替沙星和莫西沙星的敏感性彼此相当(p = 0.312),并且与头孢唑林 - 妥布霉素(p = 0.479)、加替沙星 - 头孢唑林(p = 0.134)和莫西沙星 - 头孢唑林(p = 0.412)联合用药的潜在敏感性相当。
莫西沙星或加替沙星单药治疗可作为细菌性角膜炎一线经验性治疗中头孢唑林 - 妥布霉素联合用药的有效替代方案。在第四代氟喹诺酮类药物中添加头孢唑林的价值有限。